Equitable Access to High-Cost Pharmaceuticals - 1st Edition - ISBN: 9780128119457

Equitable Access to High-Cost Pharmaceuticals

1st Edition

Authors: Zaheer-Ud-Din Babar
Paperback ISBN: 9780128119457
Imprint: Academic Press
Published Date: 26th February 2018
Page Count: 248
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

Key Features

  • Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
  • Incorporates existing guidelines and recommendations by international organizations
  • Compares and contrasts how different countries fund and police high-cost drug access
  • Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
  • Reviews novel pharmaceuticals of current research interest


Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics

Table of Contents

1. Access to high cost medicines and public health policies: A general overview
2. Health technology assessment, comparative effectiveness research
3. Evolution of UK policy to manage high drug costs
4. Managed entry agreement and high cost medicines (European perspective)
5. Setting a public health based medicines development agenda to support access to high cost medicines
6. Intellectual property issues, human right approaches and access to new essential medicines
7. Access to high cost medicines in Portugal
8. Access to high cost medicines in Africa with focus/case study of Uganda
9. Access to Biosimilars
10. Access to high cost medicines in Europe
11. Access to high cost medicines in Australia
12. Access to high-cost medicines in New Zealand
13. Access to high-cost medicines: a review of the literature (2011-2017)


No. of pages:
© Academic Press 2018
Academic Press
Paperback ISBN:

About the Author

Zaheer-Ud-Din Babar

Zaheer-Ud-Din Babar is Professor in Medicines and Healthcare at the Department of Pharmacy, University of Huddersfield, United Kingdom. He is globally recognized for his research in pharmaceutical policy and practice, including the quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. Previously he was the Head of Pharmacy Practice at School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a Ph.D. in pharmacy practice, Dr. Babar is the recipient of prestigious “Research Excellence Award” from the University of Auckland. He has active research collaborations and linkages in over 30 countries including in World’s leading Universities such as Boston University School of Public Health, Harvard Medical School, Austrian Health Institute, University of Auckland, Monash University and at the University of Sydney. He has published over 150 papers, book chapters, conference papers including in high impact journals such as PLoS Medicine and in Lancet Oncology. Dr. Babar has acted as an advisor for World Health Organization, Health Action International, the International Union Against Tuberculosis and Lung Disease, World Bank, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. His recent work includes a number of high-quality books including "Economic evaluation of pharmacy services", ”Pharmaceutical prices in 21st century”, “ Pharmacy Practice Research Methods” and “Pharmaceutical policies in countries with developing healthcare systems. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe. He is the Editor in Chief of Encyclopedia of Pharmacy Practice and Clinical Pharmacy, which is due to be published by Elsevier in early 2019.The Encyclopedia is comprehensive in nature and it aims to cover multiple stream and domains including pharmacy practice, sociobehavioural, and administrative pharmacy, pharmacoepidemiology, clinical pharmacy and therapeutics and issues related to pharmacy education, professional standards, and workforce. Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at z.babar@hud.ac.uk

Affiliations and Expertise

Department of Pharmacy, University of Huddersfield, Huddersfield, UK and Founding editor, Journal of Pharmaceutical Policy and Practice

Ratings and Reviews